Roche pledges $700 million to join research on the drug bexobrutideg.

Potentially worth up to $2.3 billion, the collaboration is a bet that drugs able to eliminate the “BTK” enzyme will prove superior to existing medicines that block its activity.

Roche pledges $700 million to join research on the drug bexobrutideg.